Vital Images Launches Vitrea(R) Enterprise Suite, Version 6.0

Vital Images Launches Vitrea(R) Enterprise Suite, Version 6.0
New Clinical and Platform Features Increase Value Across the Healthcare Enterprise 

MINNEAPOLIS, Nov 28, 2010 (GlobeNewswire via COMTEX) -- Vital Images, Inc., a leading provider of advanced visualization solutions, will release Vitrea(R) Enterprise Suite (VES), Version 6.0 at the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), in Chicago (booth 7914, North Hall). Version 6.0 provides in-depth, clinical functionality via a unique, modular architecture that delivers optimal performance and thin-client access to applications and image data.

The VES platform separates rendering, processing and data storage to deliver sustained quality of service for clinicians regardless of the number of simultaneous users or data load on the system. For IT departments, the modular platform cost-effectively scales to meet the specific imaging needs of the healthcare institution. As the only advanced virtualization solution certified VMware Ready(TM), VES complements virtualization strategies to support decreased total cost of ownership, increased productivity and simplified disaster recovery.

New clinical features in VES 6.0 extend multi-modality and oncology capabilities by introducing Dynamic MR*, XA 3D Angio, and Oncology Fusion, which allows users to visualize, quantify and track tumors using fused CT, MR, PET and SPECT images. A new Denoising filter also allows users to toggle between pre- and post- filtered images "on the fly" for improved diagnostic confidence.

"Version 6.0 features deep clinical functionality built on a truly scalable, modular platform," said Michael H. Carrel, president and chief executive officer at Vital Images. "Vitrea Enterprise Suite is uniquely capable of delivering both value and performance for the growing, changing imaging needs of the healthcare enterprise."

VES 6.0 also includes a new multi-chamber cardiovascular solution, which enables comprehensive assessment of cardiovascular function and structures for adults and pediatrics. The endovascular stent planning application has been enhanced, adding TAA to AAA capabilities. Version 6.0 enhances VES's existing clinical applications, intuitive user interface and automated workflows to speed diagnosis, communication and collaboration for efficient, informed decision making.

VES 6.0 can be seen at Vital Images' booth number 7914 in the North Hall as well as in partner booths throughout the RSNA show floor. For more information, visit Vital Images at RSNA or online at www.vitalimages.com.

*Approved for use in the European Union and Canada.

About Vital Images

Vital Images, Inc. is a leading provider of advanced visualization and analysis software for physicians and healthcare specialists. The company's software provides users productivity and communication tools to improve patient care that can be accessed throughout the enterprise anytime, anywhere via the Web. Established in 1988 and headquartered in Minneapolis, Vital Images also has offices in Europe and Asia. For more information, visit www.vitalimages.com.

Vital Images(R) and Vitrea(R) are registered trademarks of Vital Images, Inc. Vital Images disclaims any proprietary interest in the marks and names of others.

The Vital Images, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5843

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to enjoy the protection of the safe harbor for forward-looking statements provided by that Act. These statements involve risks and uncertainties which could cause results to differ materially from those projected, including but not limited to dependence on market growth, challenges associated with international expansion, the ability to predict product, customer and geographic sales mix, fluctuations in interest rates, regulatory approvals, the timely introduction, availability and acceptance of new products, the impact of competitive products and pricing, dependence on major customers, the ability to successfully manage operating costs, fluctuations in quarterly results, approval of products for reimbursement and the level of reimbursement, and other factors detailed from time to time in Vital Images' SEC reports, including its annual report on Form 10-K for the year ended December 31, 2009. Vital Images encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this release. The forward-looking statements made in this release are made only as of the date of this release, and the company undertakes no obligation to update them to reflect subsequent events or circumstances.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Vital Images, Inc.

CONTACT:  Vital Images, Inc.
Kim Tucker
(952) 487-9500
www.vitalimages.com

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.